Preclinical Studies of LB-102 (N-Methyl Amisulpride-R) (NMA) for Treatment of Major Depression, Bipolar Disorder, Schizophrenia, OCD and Behavioral Disturbance of Alzheimer's Disease

Project: Research project

Project Details


LB-102 (R), amisulpride and fluoxetine in the Porsolt FST in wild type mice, acutely stressed mice and scPCP-treated mice. LB102 will be tested to determine the effective dose (ED) and the subeffective dose (SED). We will also determine the ineffective dose if LB102 alone is ineffective in our treatment resistant model.The SED will be used to determine the ability of SEDs of LB-102 to augment the efficacy of SEDs of fluoxetine and lurasidone, an atypical APD widely used to treat bipolar depression and major depression, both responsive and treatment resistant types, as augmentation treatment.
Effective start/end date12/1/2011/30/21


  • LB Pharmaceuticals, Inc. (Meltzer AGMT 12/15/20)


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.